Medication-Induced Movement
Medication-Induced Movement
Full criteria not included in this record
Full criteria not included in this record
Full criteria not included in this record
Full criteria not included in this record
A. Abnormal and prolonged contraction of muscles of eyes, face, neck, limbs, or trunk developing in association with medication use B. Symptoms developed within a few days of starting or raising dose of medication, or reducing medication used to treat extrapyramidal symptoms
A. Dopamine antagonist exposure (antipsychotic or antiemetic) and development of severe muscle rigidity and elevated temperature B. ≥2 of: diaphoresis; dysphagia; tremor; incontinence; change in level of consciousness (confusion to coma); mutism; tachycardia; elevated/labile BP; leukocytosis; elevated CK C. Not attributable to another substance or medical/neurological condition
Mild; Moderate; Severe; With oculogyric crisis
Associated with antipsychotic exposure; Associated with dopaminergic withdrawal; With severe rhabdomyolysis; Severity (Mild / Moderate / Severe)
Tardive dystonia (develops after months/years of antipsychotic use; persists after cessation); Primary torsion dystonia (genetic; no medication link); NMS (hyperthermia + rigidity + autonomic instability - systemic features distinguish)
Serotonin syndrome (hyperthermia + clonus + diaphoresis + hyperreflexia - starts within 24 hrs; clonus distinguishes from NMS rigidity); Malignant hyperthermia (anaesthetic trigger; volatile agents/suxamethonium; ryanodine receptor mutation); Lethal catatonia (treatment with ECT; NMS and lethal catatonia may overlap)